Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01398423 · ClinicalTrials.gov registry record · Phase 2

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

A Phase 2 study, sponsored by InVasc Therapeutics.

Completed
Registry status
Phase 2
Development phase
88
Enrollment target

NCT01398423: Completed Phase 2 study, sponsored by InVasc Therapeutics.

NCT01398423 is a Phase 2 study that has completed, run by InVasc Therapeutics. The registered enrollment target is 88 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01398423, a Phase 2 study, has completed, sponsored by InVasc Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target

Study Summary

A randomized, double-blind, active control trial to determine the safety, efficacy and pharmacokinetics of INV-144 versus losartan potassium plus placebo in subjects with hypertension and Type 2 diabetes mellitus with nephropathy as evidenced by albuminuria.

Primary Outcome

Safety will be monitored throughout the study by evaluation of adverse events (AEs), physical examinations (PEs), clinical laboratory results, vital signs, and electrocardiograms (ECGs).

Interventions

  • DRUG Active Control
  • DRUG INV-144

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2011-06
Est. Completion 2012-07
Phase Phase 2
InVasc Therapeutics

3 total trials

What the finished NCT01398423 record still lists

NCT01398423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower).

The record links to 0 conditions, and to 2 interventions - of which Active Control is the first listed.

NCT01398423 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01398423 about?

NCT01398423 is a clinical study titled "INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria". A randomized, double-blind, active control trial to determine the safety, efficacy and pharmacokinetics of INV-144 versus losartan potassium plus placebo in subjects with hypertension and Type 2 diabetes mellitus with nephropathy as evidenced by albuminuria.

What is the current status of trial NCT01398423?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2011-06. Estimated completion is 2012-07.

What interventions are being tested in trial NCT01398423?

The interventions under investigation include: Active Control (DRUG), INV-144 (DRUG).

Who is sponsoring clinical trial NCT01398423?

This trial is sponsored by InVasc Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01398423's enrollment target sits among peer trials

88 803rd of 2000 higher than 1,191 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01398423, the US trial registry maintained by the National Library of Medicine. NCT01398423 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.